Rivista di formazione e aggiornamento professionale del pediatra e del medico di base, fondata nel 1982. In collaborazione con l'Associazione Culturale Pediatri.
Login Abbonamenti Pubblicazioni Carrello Registrazione Perché registrarsi? Contatti

Vaccinare

PDF

Vaccinazione contro la parotite epidemica

B. Maspes, R. Menta

Ottobre 1998 - pagg. 547 -548

Bibliografia

SC: The interruption of transmission of indigenous measles in the United States during
1993. Pediatr Infect Dis J 17, 363-6, 1998.
2. Istituto Nazionale di Statistica: Statistiche della Sanità, anno 1993. Annuario n. 9, 207, 1996.
3. CDC Atlanta: Progress toward elimination of measles from the Americas. MMWR 47 (10), 189-193, 1998.
4. CDC Atlanta: Recommended childhood immunization schedule - United States, 1998. MMWR 47 (1), 8-12, 1998.
5. Forsey T, Health AB, Minor PD: A European collaborative study to assess the proficiency of laboratory estimates of potency of live measles, mumps and rubella tri-valent vaccines. Biologicals 21, 239-249, 1993.
6. Minor PD: Laboratory tests of mumps vaccines. Biologicals 25, 35-40, 1997.
7. Gray JA, Burns SM: Mumps meningitis following measles, mumps and rubella immunization. Lancet 98, 1989.
8. Von Muhlendahl KE, et al: Mumps meningitis following measles, mumps and rubella immunization. Lancet 394-395, 1989.
9. Nalin DR: Mumps vaccine complications: which strain? Lancet 1396, 1989.
10. Ehrengut W. Mumps vaccine and meningitis. Lancet 751, 1989.
11. Mumps meningitis and MMR vaccination. Lancet 1015-1016, 1989.
12. Mumps meningitis possibly vaccine related - Ontario. Canada Diseases Weekly Report 14-46, 209-211, 1988.
13. Sugiura A, Yamada A: Aseptic meningitis as a complication of mumps vaccination. Pediatr Infect Dis J 10, 209-213, 1991.
14. Brown EG, Fusesz J, Dimock K, Yarosh W, Contreras G: Nucleotide sequence analysis of Urabe mumps vaccine strain that caused meningitis in vaccine recipients. Vaccine 9, 840-842, 1991.
15. Fujinaga T, Motegi Y, Tamura H, Kuroume T: A prefecture-wide survey of mumps meningitis associated with measles, mumps and rubella vaccine. Pediatr Infect Dis J 10, 204-209, 1991.
16. Tabin PR, Berclaz JP, Dupuis G, Peter O: Réponse immune à divers vaccins anti-ourliens. Revue Médicale de la Suisse Romande 113, 981-984, 1993.
17. Euro-Surveillance - European Communicable Disease Bulletin: Mumps epidemic in Portugal despite high vaccine coverage - Preliminary report. 1 (no.4), 1996.
18. Boletin Epidemiologico Semanal - Red Nacional de vigilancia epidemiolgica de Espana centro national de epidemiologia. Situacion de la parotitis en Espana durante
1996. 5 (no.2), 13, 1997.
19. Briss PA, Fehrs LJ, Parker RA, et al: Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine - induced immunity. J Infect Dis 169, 77-82, 1994.
20. CDC Atlanta. Summary of notifiable diseases, United States 1993. MMWR 42 (53), 3, 1993.
21. Peltola H, Heinonen OP, Valle M, et al: The elimination of indigenous measles, mumps and rubella from Finland by a 12- year, two-dose vaccination program. N Engl J Med 331 (21), 1397-1402, 1994.
22. Gay N, Miller E, Hesketh L, et al: Mumps surveillance in England and Wales supports introduction of two dose vaccination schedule. Communicable Disease Report 7 (2), 1997.
23. Schwarzer S, Reibel S, Lang AB, et al: Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccine. Vaccine 16 (2/3), 298-304, 1998.